Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-09-21

Clinical Trial Update: Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating intranasal oxytocin effects on satiety signaling in people with schizophrenia; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • intranasal oxytocin (oxytocin)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED | Results posted: 2017-09-21